- Home
- CAPL vs JANX Comparison
CAPL vs JANX Comparison
Compare CAPL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAPL | JANX |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 858.1M | 840.4M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAPL | JANX |
|---|---|---|
| Price | $22.33 | $16.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | 31.3K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | ★ 96.15 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,869,806,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.80 | N/A |
| P/E Ratio | $86.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.61 | $12.12 |
| 52 Week High | $23.34 | $35.34 |
Technical Indicators
Market Signals| Indicator | CAPL | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 66.25 |
| Support Level | $21.47 | $13.00 |
| Resistance Level | $23.01 | $16.60 |
| Average True Range (ATR) | 0.48 | 0.72 |
| MACD | 0.03 | 0.22 |
| Stochastic Oscillator | 72.85 | 82.88 |
Price Performance
Historical ComparisonAbout CAPL CrossAmerica Partners
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments, namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.